Bard XT Stent Received CE Mark Approval.MURRAY HILL, N.J.--(BUSINESS WIRE)--Feb. 17, 1998--C. R. Bard, Inc. (NYSE-BCR) announced today that the Irish Notified Body (NSAI NSAI Nashville Songwriters Association International NSAI National Standards Authority of Ireland NSAI Non-Steroidal Anti-Inflamatory ) has approved the Bard XT Coronary Stent coronary stent Intracoronary stent Cardiology An expandable tubular device which can be inserted percutaneously, and left within a coronary artery lumen to maintain its patency Pros Clinical and angiographic outcomes are better with intracoronary artery stent for CE Marking. The XT stent is available outside the United States in several configurations. Because of its unique patented loading device, the XT stent can be packaged and sold individually. It is also packaged and sold premounted on either a rapid exchange or an over-the-wire balloon catheter balloon catheter n. A catheter with an inflatable balloon at its tip, used especially to expand a partially obstructed blood vessel or bodily passage and to measure blood pressure in a blood vessel. Also called balloon-tip catheter. . "The CE Mark approval is yet another milestone in our progress toward expanding our worldwide presence in interventional cardiology," commented William H. Longfield, chairman and chief executive officer. "We believe that the versatility of the XT stent's modular design will propel it to become the stent of choice. Bard continues to move forward in advancing new technologies for better patient outcomes." C. R. Bard C. R. Bard, Inc. (NYSE: BCR) is one of the large S&P 500 companies of the United States, a surgical specialties and hospital medical device manufacturer in Murray Hill, New Jersey. It is named after its founder, who sold the company within only a few years of its founding. , Inc., headquartered in Murray Hill, New Jersey
This press release contains forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. Management would request that everyone refer to our 1997 Third Quarter Form 10-Q for Bard's detailed statement with regard to forward-looking statements. CONTACT: C. R. Bard, Inc., Murray Hill E. L. Parker, (908) 277-8059 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion